Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00993070
Recruitment Status : Completed
First Posted : October 9, 2009
Last Update Posted : May 9, 2012
Bangkok Drug company
Information provided by (Responsible Party):
Kongkiat Kulkantrakorn, Thammasat University

Brief Summary:
Painful diabetic neuropathy is the most common cause of neuropathic pain. 0.075% topical capsaicin has been used to treat the pain, but there is no data in lower concentration. This is the efficacy and safety of 0.025% topical capsaicin in treatment of painful diabetic polyneuropathy.

Condition or disease Intervention/treatment Phase
Diabetic Polyneuropathy Drug: Capsaicin Drug: placebo Phase 2 Phase 3

Detailed Description:

Patient is randomized to receive either 0.025% topical capsaicin or vehicle control (placebo) for 8 weeks. After one week wash-out period, patients will be switched to the other group for 8 weeks.

Outcome will be assessed by visual analog scale, neuropathic pain scale, SF-MPQ, SF-36. Safety and tolerability will be recorded.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Crossover, Double Blinded, Placebo Controlled Trial of Topical Capsaicin in Treatment of Painful Diabetic Neuropathy
Study Start Date : October 2009
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Capsaicin
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Capsaicin Drug: Capsaicin
0.025% topical capsaicin applied 4 times per day for 8 weeks
Other Name: Capsika gel
Placebo Comparator: placebo Drug: placebo
vehicle gel, applied 4 times per day for 8 weeks

Primary Outcome Measures :
  1. Pain relief from pain score reduction, using visual analog scale (VAS) [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Overall clinical improvement, measured by Clinician Global Impression of Change(CGIC) [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of type 2 Diabetes mellitus
  • Peripheral neuropathy
  • Stabilized on pain medication for at least one month
  • No previous invasive intervention for pain relief

Exclusion Criteria:

  • Local wound or skin abnormality in the applicable area
  • Allergic to capsaicin
  • Refuse to participate or give consent
  • Has other significant disease or receive medication that may worsen neuropathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00993070

Thammasat University Hospital
Pathumthani, Thailand, 12120
Sponsors and Collaborators
Thammasat University
Bangkok Drug company
Principal Investigator: Kongkiat Kulkantrakorn, MD Thammasat University

Responsible Party: Kongkiat Kulkantrakorn, Associate Professor, Thammasat University Identifier: NCT00993070     History of Changes
Other Study ID Numbers: MTU-I-1-45/52
First Posted: October 9, 2009    Key Record Dates
Last Update Posted: May 9, 2012
Last Verified: May 2012

Keywords provided by Kongkiat Kulkantrakorn, Thammasat University:
diabetic polyneuropathy
neuropathic pain

Additional relevant MeSH terms:
Diabetic Neuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Dermatologic Agents
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs